Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Meteoric-Biopharmaceuticals"

4 News Found

We plan to expand into the US market this year: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | March 03, 2022

We plan to expand into the US market this year: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry

Clinical Trials in the New Normal
Opinion | March 24, 2022

Clinical Trials in the New Normal

The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay

Latest Stories

Jubilant Pharmova to close manufacturing operations of Solid dosage formulation facility of Jubilant Cadista USA

Shilpa Medicare launches Pemetrexed injection

Fresenius Kabi USA flies complaint against NATCO Pharma

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging